首頁/股票/BCAB

BCAB

USD

BioAtla Inc. Common Stock

$0.673+0.023 (3.615%)

即時價格

Healthcare

生物科技

美國

價格圖表

Loading Chart...

關鍵指標

市場指標

公司基本面

交易統計

市場指標

開盤

$0.650

最高

$0.678

最低

$0.613

交易量

0.11M

公司基本面

市值

39.5M

行業

生物科技

國家

United States

交易統計

平均交易量

1.01M

交易所

NCM

貨幣

USD

52週範圍

最低 $0.24當前 $0.673最高 $2.525

相關新聞

2025年10月23日 · 下午12:00

GlobeNewswire

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

2025年10月3日 · 下午01:00

GlobeNewswire

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its